Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy IMMP?
Source: NASDAQ.COM
- Orphan Drug Designation: Immutep's immunotherapy candidate Eftilagimod alfa (efti) has received Orphan Drug Designation from the U.S. FDA for treating soft tissue sarcoma, a rare cancer with significant unmet medical needs.
- Clinical Trial Results: The Phase II EFTISARC-NEO trial showed that in 38 evaluable patients, the therapy achieved a median tumor hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and the historical benchmark of ~15%, indicating strong efficacy.
- Market Exclusivity Benefits: The FDA's Orphan Drug program offers regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity, which could provide substantial momentum for Immutep's further research and development in the soft tissue sarcoma space.
- Stock Performance: IMMP shares have traded between $0.29 and $3.53 over the past year, currently priced at $0.60, reflecting a 93.01% increase, indicating strong market optimism regarding the drug's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.580
Low
12.00
Averages
12.00
High
12.00
Current: 0.580
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, allowing affected investors to seek compensation without upfront costs.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, resulting in an 82.6% drop in ADR price to $0.48, reflecting severe market pessimism about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit against Immutep to recover investor losses, demonstrating its strong commitment to protecting investor rights and interests.
- Firm Reputation: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its leadership and expertise in the field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency.
- Stock Price Plummet: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, which may encourage more impacted investors to join the lawsuit.
- Firm's Track Record: Known for its success in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant legal risks that could impact the company's market reputation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, which severely undermines investor confidence and may trigger further litigation.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to join without any out-of-pocket fees, aiming to provide legal support for affected investors and enhance their recovery rights.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, which may attract more investors seeking legal assistance.
See More
Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation
- Orphan Drug Designation: Immutep's immunotherapy candidate Eftilagimod alfa (efti) has received Orphan Drug Designation from the U.S. FDA for treating soft tissue sarcoma, a rare cancer with significant unmet medical needs.
- Clinical Trial Results: The Phase II EFTISARC-NEO trial showed that in 38 evaluable patients, the therapy achieved a median tumor hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and the historical benchmark of ~15%, indicating strong efficacy.
- Market Exclusivity Benefits: The FDA's Orphan Drug program offers regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity, which could provide substantial momentum for Immutep's further research and development in the soft tissue sarcoma space.
- Stock Performance: IMMP shares have traded between $0.29 and $3.53 over the past year, currently priced at $0.60, reflecting a 93.01% increase, indicating strong market optimism regarding the drug's prospects.
See More
Immutep Receives FDA Orphan Drug Designation
- Orphan Drug Designation: Immutep announced that its eftilagimod alfa (efti) has received FDA Orphan Drug Designation for soft tissue sarcoma, a rare cancer with significant unmet medical needs, which is expected to provide market exclusivity and tax incentives for the company.
- Clinical Trial Results: In the EFTISARC-NEO Phase II trial, the median tumor hyalinization/fibrosis of 38 evaluable patients reached 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of 15%, indicating the potential of efti in treating soft tissue sarcoma.
- Safety and Efficacy: The trial results demonstrated that efti, when used in combination with radiotherapy and KEYTRUDA®, exhibited a favorable safety profile with no delays to planned surgeries, further enhancing its clinical applicability and market appeal.
- Future Clinical Plans: Immutep's CEO Marc Voigt stated that the FDA designation provides a direct opportunity for efti to enter late-stage studies for soft tissue sarcoma, although the company is currently reviewing the outcomes of its Phase III TACTI-004 trial to determine future clinical trial directions.
See More
FDA Grants Orphan Drug Designation to Immutep's Eftilagimod Alfa
- Orphan Drug Designation: The FDA has granted Orphan Drug Designation to Immutep's Eftilagimod Alfa based on promising trial results for treating soft tissue sarcoma, which is expected to provide the company with 7 years of market exclusivity and tax incentives, significantly enhancing future revenue potential.
- Clinical Trial Success: In the Phase II EFTISARC-NEO trial, 51.5% of tumor tissue in 38 patients showed signs of fibrosis, exceeding the 35% target, which not only validates Efti's efficacy but also lays a solid foundation for future market promotion.
- Stock Price Volatility: Despite an 82% plunge in IMMP's stock price due to the termination of the TACTI-004 trial in March, shares surged approximately 150% in pre-market trading on Wednesday following the FDA's designation, reflecting strong market confidence in the drug.
- Investor Sentiment Shift: Retail investor sentiment on IMMP flipped from 'bearish' to 'extremely bullish', with some anticipating new partnerships or acquisitions as a result of the latest news, although there are concerns that the TACTI-004 failure may still define the long-term trend.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, allowing affected investors to seek compensation without upfront costs.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, resulting in an 82.6% drop in ADR price to $0.48, reflecting severe market pessimism about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit against Immutep to recover investor losses, demonstrating its strong commitment to protecting investor rights and interests.
- Firm Reputation: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its leadership and expertise in the field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency.
- Stock Price Plummet: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, which may encourage more impacted investors to join the lawsuit.
- Firm's Track Record: Known for its success in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant legal risks that could impact the company's market reputation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, which severely undermines investor confidence and may trigger further litigation.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to join without any out-of-pocket fees, aiming to provide legal support for affected investors and enhance their recovery rights.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, which may attract more investors seeking legal assistance.
See More
Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation
- Orphan Drug Designation: Immutep's immunotherapy candidate Eftilagimod alfa (efti) has received Orphan Drug Designation from the U.S. FDA for treating soft tissue sarcoma, a rare cancer with significant unmet medical needs.
- Clinical Trial Results: The Phase II EFTISARC-NEO trial showed that in 38 evaluable patients, the therapy achieved a median tumor hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and the historical benchmark of ~15%, indicating strong efficacy.
- Market Exclusivity Benefits: The FDA's Orphan Drug program offers regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity, which could provide substantial momentum for Immutep's further research and development in the soft tissue sarcoma space.
- Stock Performance: IMMP shares have traded between $0.29 and $3.53 over the past year, currently priced at $0.60, reflecting a 93.01% increase, indicating strong market optimism regarding the drug's prospects.
See More
Immutep Receives FDA Orphan Drug Designation
- Orphan Drug Designation: Immutep announced that its eftilagimod alfa (efti) has received FDA Orphan Drug Designation for soft tissue sarcoma, a rare cancer with significant unmet medical needs, which is expected to provide market exclusivity and tax incentives for the company.
- Clinical Trial Results: In the EFTISARC-NEO Phase II trial, the median tumor hyalinization/fibrosis of 38 evaluable patients reached 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of 15%, indicating the potential of efti in treating soft tissue sarcoma.
- Safety and Efficacy: The trial results demonstrated that efti, when used in combination with radiotherapy and KEYTRUDA®, exhibited a favorable safety profile with no delays to planned surgeries, further enhancing its clinical applicability and market appeal.
- Future Clinical Plans: Immutep's CEO Marc Voigt stated that the FDA designation provides a direct opportunity for efti to enter late-stage studies for soft tissue sarcoma, although the company is currently reviewing the outcomes of its Phase III TACTI-004 trial to determine future clinical trial directions.
See More
FDA Grants Orphan Drug Designation to Immutep's Eftilagimod Alfa
- Orphan Drug Designation: The FDA has granted Orphan Drug Designation to Immutep's Eftilagimod Alfa based on promising trial results for treating soft tissue sarcoma, which is expected to provide the company with 7 years of market exclusivity and tax incentives, significantly enhancing future revenue potential.
- Clinical Trial Success: In the Phase II EFTISARC-NEO trial, 51.5% of tumor tissue in 38 patients showed signs of fibrosis, exceeding the 35% target, which not only validates Efti's efficacy but also lays a solid foundation for future market promotion.
- Stock Price Volatility: Despite an 82% plunge in IMMP's stock price due to the termination of the TACTI-004 trial in March, shares surged approximately 150% in pre-market trading on Wednesday following the FDA's designation, reflecting strong market confidence in the drug.
- Investor Sentiment Shift: Retail investor sentiment on IMMP flipped from 'bearish' to 'extremely bullish', with some anticipating new partnerships or acquisitions as a result of the latest news, although there are concerns that the TACTI-004 failure may still define the long-term trend.
See More
